Queensland generated the most medicinal cannabis approvals under the Special Access Scheme in November, the first time it has done so in six months.
The Therapeutic Goods Administration (TGA) rubber stamped 5,320 SAS-B applications from the sunshine state out of 11,915 nationwide.
Victoria, which has led the way for the past five months, generated 4,150.
The total number of November approvals was the second highest of 2023, taking the year-to-date total to 122,570, surpassing both 2021 and 2022 figures with a month of the year remaining.
High-THC, category 5 medicine contributed almost half the approvals last month, with CBD-only generating 19% and category 3 (a balance of CBD and THC) making up 17% of the total.
Oral solutions remained the most-prescribed format among SAS-B applications, accounting for 50% of approvals, with flower at 36%.
Inhalation and capsules accounted for 7% and 2% respectively.
In line with previous months, chronic pain was the most common condition treated with medicinal cannabis (42%), followed by anxiety (33%), sleep disorder (8%) and PTSD (2%).
The SAS-B applications were generated by 906 subscribers.
